Tacrolimus and Pimecrolimus: Revolutionary New Topical Immunomodulators for Skin Disorders

International Pediatrics

Volumn 19, Issue 1, 2004, Pages 7-13

  Burkhart, Craig N ^a,b   Gottwald, Lorie ^b   Nelson, Lois ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Pimecrolimus cream; Skin diseases; Steroids; Tacrolimus ointment; Topical immunomodulators

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; DIFLORASONE DIACETATE; IMMUNOMODULATING AGENT; IMMUNOPHILIN; PIMECROLIMUS; TACROLIMUS;

ACNE; ATOPIC DERMATITIS; BREAST FEEDING; CLINICAL TRIAL; CONTACT ALLERGY; CREAM; CYTOKINE RELEASE; DRUG EFFICACY; FLU LIKE SYNDROME; FOLLICULITIS; HEADACHE; HUMAN; HYPERTENSION; IMMUNE RESPONSE; NEPHROTOXICITY; NEUROTOXICITY; PHOTOALLERGY; PHOTOSENSITIVITY; PREGNANCY; REVIEW; SIGNAL TRANSDUCTION; SKIN ATROPHY; SKIN DISEASE;

EID: 1542514785     PISSN: 08856265     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Luger T. Treatment of immune-mediated skin diseases: future perspectives. Europ J Dermatol 2001;11:343-7.
2. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opinion Invest Drugs 2000;9:69-77.
3. Bornhovd EC, Schuller E, Bieber T, Wollenberg A. Immunosuppressive macrolides and their use in dermatology. Hautarzt 2000;51:646-54.
4. Luger T, VanLeent EJ, Graeber M, Hedgecock S, Thurston M, Kandra A, Berth-Jones J, Bjerke J, Christophers E, Knop J, Knulst AC, Morren M, Morris A, Reitamo S, Roed-Petersen J, Schoepf E, Thestrup-Pedersen K, VanDerValk PG, Bos JD. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001;144:788-94.
5. Morris RE. Mechanisms of action of new immunosuppressive drugs. Kidney Int 1996;49(Supp 53):26-38.
6. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506) and cyclosporin A as immunosuppressive agents. Transplant Fev 1995;9:63-76.
7. Meingassner JG, Stutz A. Anti-inflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 1992;99:486-9.
8. Sengoku T, Morita K, Sato S, Sakuma S, Ogawa T, Hiroi J. Effects of tacrolimus ointment of type I (immediate and late) and IV (delayed) cutaneous allergic reactions in mice. Folia Pharmacol Jpn 1998;112:221-32.
9. Ranaweera A. Pimecrolimus-long-term management of inflammatory skin diseases. Inpharma 2001;1281:11-12.
10. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-21.
11. Reitamo S, Wollenberg A, Schopf E, Perrot JL, Marks R, Ruzicka T, Christophers E, Kapp A, Lahfa M, Rubins A, Jablonska S, Rustin M. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol 2000;136:999-1006.
12. Hanifin JM, Ling MR, Langley R, Breneman D, Rafal E. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermtol 2001;44:S28-38.
13. Soter NA, Fleischer AB, Webster GF, Monroe E, Lawrence I. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol 2001;44:S39-46.
14. Paller A, Eichenfield LF, Leung DYM, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001;44:S47-57.
15. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, Beusterien M, Lawrence I. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001;44:S65-72.
16. Bekersky I, Fitzsimmons W, Tanase A, Maher RM, Hodosh E, Lawrence I. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001;44:S17-27.
17. Wellington K, Spencer CM. SDZ ASM 981. Biodrugs 2000;14:409-16.
18. Lauerman AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992;340:556.
19. Lauerma Ai, Stein B, Lee HL, Homey B, Bloom E, Maibach HI. Topical tacrolimus (FK506): percutaneous absorption and effect on allergic and irritant contact dermatitis. J Invest Dermatol 1993;110:491.
20. Queille-Roussel C, Graeber M, Thurston M, Lachapelle JM, Decroix J, de Cuyper C, Ortonne JP. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis 2000;42:349-50.
21. Suga Y, Tsuboi R, Hashimoto Y, Yoshiike T, Ogawa H. A case of ichthyosis linearis circumflexa successfully treated with topical tacrolimus. J Am Acad Dermatol 2000;42:520-2.
22. Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. Arch Dermatol 2001;137:1202-6.
23. Richter-Hintz D, Schuppe HC, Homey B, Lehmann P, Ruzicka T. Topical tacrolimus (FK 506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 2000;4:304-5.
24. Schuppe H, Richter-Hintz D, Stierle HE, Homey B, Ruzicka T, Lehmann P. Topical tacrolimus for recalcitrant leg ulcer in rheumatoid arthritis. Rheumatology 2000;39:105-6.
25. th Annual Meeting American Academy of Dermatology. Abstract 011, March 2, 2001.
26. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-40.
27. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol 1999;140:338-42.
28. Mrowietz U, Graeber M, Brautigam M, Thurston M, Wagenaar A, Weidinger G, Christophers E. The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br J Dermatol 1998;139:992-6, 1998.
29. Rappersberger K, Meingassner JG, Fialla R, Fodinger D, Sterniczky B, Rauch S, Putz E, Stutz A, Wolff K. Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 1996;106:701-10.
30. Lewis HM. Therapeutic progress. II: Treatment of psoriasis. J Clin Pharm Therap 1994;19:223-32.
31. Yamamoto T, Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Act Dermato-Venereologica 2000;80:451.
32. Remits A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in microplaque assay. Br J Dermatol 1999;141:103-7.
33. Yuzawa K, Taniguchi H, Seino K, Otsuka M, Fukao K. Topical immunosuppression in skin grafting with FK 506 ointment. Transplantation Proceedings 1996;28:1387-9.
34. Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: a preliminary report. J Am Acad Dermatol 2001;44:995-8.
35. Dale S, Shaw J. Eosinophilic pustular folliculitis. Lancet 2000;356:1235-6.
36. Lauerma AI, Maibach HI. Topical FK506; clinical potential or laboratory curiosity? Dermatology 1994;188:173-6.
37. Nghiem P. Topical immunomodulators: introducing old friends and a new ally, tacrolimus. J Am Acad Dermatol 2001;44:111-3.
38. Thiers BH. Topical tacrolimus: treatment failure in a patient with alopecia areata. Arch Dermatol 2000;136:124.
39. Freyschmidt-Paul P, Ziegler A, McElwee KJ, Happle R, Kissling S, Sundberg JP, Hoffmann R. Treatment of alopecia areata in C3H/HeJ mice with the topical immunosuppressant FK506 (tacrolimus). European J Dermatol 2001;11:405-9.
40. Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Rizicka T, Kind P. Topical tacrolimus is not effective in chronic plaque psoriasis: a pilot study. Arch Dermatol 1998;134:1101-2.
41. Kawashima H, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentration in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1.
42. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102:637-44.
43. Hanifin JM and the tacrolimus Ointment Study Group. Use of tacrolimus ointment in 3-6 year-olds with atopic dermatitis: dose escalation study. J Invest Dermatol 1998;110:681.
44. Kang S and the Tacrolimus Ointment Study Group. Tacrolimus ointment for adults with moderate to severe atopic dermatitis: a dose escalation study. J Invest Dermatol 1998;110:681.
45. Ruzicka T, Bieber T, Schopf E, Rubins A, Dobozy A, Bos JD. A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-21.
46. Bornhovd E, Burgdorf WHC, Wollenberg A. Macrolactom immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol 2001;45:736-43.
47. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:S58-64.
48. Aly F. Bacteriology of atopic dermatitis. Acta Derm Venereol 1980:60(Suppl 92):16-8.
49. Fystedt I, Stannegard IL, Stannegard O. Recurrent viral infections in patients with pastor present atopic dermatitis. Br J Dermatol 1986;114:575-82.
50. Vieluf D, Ruzicka T. Complications and diseases associated with atopic eczema. In: Ruzicka T, Ring J, Przybilla B, eds. Handbook of Atopic Eczema. Berlin, Germany: Springer-Verlag;1991:54-79.
51. Lubbe J, Pournaras CC, Saurat JH. Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment. Dermatology 2000;201:249-51.
52. Anonymous. Topical tacrolimus for treatment of atopic dermatitis. The Medical Letter 2001;43 (issue 1102): 33-34.
53. Schulz BS, Michel G, Wagner S. Increased expression of epidermal IL receptor in psoriasis: down-regulatation by FK-506 in vitro. J Immunol 1993;151:4399-4406.
54. Duncan JI. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin A, FK506, and rapamycin. J Invest Dermatol 1994;102:84-88.
55. Reitamo S, Rissanen J, Remitz A. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998;111:396-8.